Evidence map›Paper›PMID 22763756›Full record

ArticleEuropean journal of clinical pharmacology2013

High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

E Garbe, S Kloss, M Suling, I Pigeot, S Schneeweiss

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

E GarbeDepartment of Clinical Epidemiology, BIPS-Institute for Epidemiology and Prevention Research, Achterstr. 30, 28359 Bremen, Germany. garbe@bips.uni-bremen.de
S Kloss
M Suling
I Pigeot
S Schneeweiss
Leibniz Institute for Prevention Research and Epidemiology - BIPS · DEHarvard University · US

Funding

Analyzing Complex Healthcare Data to Determine Causality of Observed Drug EffectsR01LM010213 · NLM · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G. · 2009 to 2012
$1.6M
CCR NIH HHS RC1-RR028231NHLBI NIH HHS RC4-HL106373NLM NIH HHS R01-LM010213
6 · The paper itself

Abstract

purposeHigh-dimensional propensity score (hd-PS) adjustment has been proposed as a tool to improve control for confounding in pharmacoepidemiological studies using longitudinal claims databases. We investigated whether hd-PS matching improved confounding by indication in a study of Cox-2 inhibitors (coxibs) and traditional nonsteroidal anti-inflammatory drugs (tNSAIDs) and their association with the risk of upper gastrointestinal complications (UGIC).

methodsIn a cohort study of new users of coxibs and tNSAIDs we compared the effectiveness of these drugs to reduce UGIC using hd-PS matching and conventional propensity score (PS) matching in the German Pharmacoepidemiological Research Database.

resultsThe unadjusted rate ratio (RR) of UGIC for coxib users versus tNSAID users was 1.21 [95 % confidence interval (CI) 0.91-1.61]. The conventional PS matched cohort based on 79 investigator-identified covariates resulted in a RR of 0.84 (0.56-1.26). The use of the hd-PS algorithm based on 900 empirical covariates further decreased the RR to 0.62 (0.43-0.91).

conclusionsA comparison of hd-PS matching versus conventional PS matching resulted in improved point estimates for studying an intended treatment effect of coxibs versus tNSAIDs when benchmarked against results from randomized controlled trials.

Indexed as

Propensity ScoreAdultAgedAlgorithmsAnti-Inflammatory Agents, Non-SteroidalBenchmarkingComparative Effectiveness ResearchConfidence IntervalsConfounding Factors, EpidemiologicCyclooxygenase 2 InhibitorsFemaleGastrointestinal DiseasesGermanyHumansLogistic ModelsMaleAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 Inhibitors

Identifiers

PMID22763756
OpenAlexW1998368672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.